Efficacy Data of SNT-317 Presented

Santhera tests in merosin deficient mouse models with omigapil showed decreased apoptosis (programmed cell death) and improved survival outcome. Co-administration with mini-agrin had additive beneficial effects. Santhera presents efficacy data of SNT-317 (omigapil) in CMD. Santhera pharmaceutical and partner TREAT-NMD, announced positive preclinical data. Omigapil is an oral compound, released by Novartis, with European Orphan Drug Status for treatment of both merosin deficient CMD and Ullrich CMD.

http://www.santhera.com/index.php?docid=212&vid=&lang=en&newsdate=200805&newsid=1222758&newslang=en

http://hugin.info/137261/R/12222758/257888.pdf

This entry was posted in Research News. Bookmark the permalink. Both comments and trackbacks are currently closed.
  • Congenital Muscular Dystrophy

    A group of diseases causing muscle weakness at birth. Several defined genetic mutations cause muscles to break down faster than they can repair or grow. A child with CMD may have various neurological or physical impairments. Some children never gain the ability to walk, while others lose the ability as they grow older. Learn more...

  • Register Now!